Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor

Many drugs are promiscuous and bind to multiple targets. On the one hand, these targets may be linked to unwanted side effects, but on the other, they may achieve a combined desired effect (polypharmacology) or represent multiple diseases (drug repositioning). With the growth of 3D structures of dru...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2020-05, Vol.15 (5), p.e0233089
Hauptverfasser:	Adasme, Melissa F, Parisi, Daniele, Van Belle, Kristien, Salentin, Sebastian, Haupt, V Joachim, Jennings, Gary S, Heinrich, Jörg-Christian, Herman, Jean, Sprangers, Ben, Louat, Thierry, Moreau, Yves, Schroeder, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors Agammaglobulinaemia Tyrosine Kinase - metabolism Angiogenesis Antineoplastic agents Autoimmune diseases B cells B-Lymphocytes - metabolism Binding sites Biology and Life Sciences Biotechnology Bruton's tyrosine kinase Cancer Cancer therapies Cell activation Chemotherapy Conservation Cytotoxicity Deactivation Disease Diseases Drug interactions Drug Repositioning - methods Drugs Genes Growth factor receptors Growth factors Humans Ibrutinib Identification and classification Immunology Inactivation Inhibitor drugs Interfaces Jurkat Cells Kidney cancer Kinases Laboratories Lupus Lymphocytes B Lymphoma Medicine and Health Sciences Multiple myeloma Nephrology Pazopanib Pharmacological research Phenols (Class of compounds) Promiscuity Protein-tyrosine kinase Pyrazoles - chemistry Pyrazoles - pharmacology Pyrimidines - chemistry Pyrimidines - pharmacology Research and Analysis Methods Rheumatoid arthritis RNA Interference Side effects Signal Transduction - drug effects Sorafenib Structure (Literature) Structure-activity relationships (Pharmacology) Sunitinib Suramin - chemistry Suramin - pharmacology Target recognition Targeted cancer therapy Therapeutic targets Time Tyrosine Vascular endothelial growth factor Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors Vascular Endothelial Growth Factor Receptor-2 - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!